Adjuvant darolutamide prolongs survival in metastatic, hormone-sensitive prostate cancer
Researchers from a phase 3 clinical trial report that addition of the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy significantly prolongs the survival of men with metastatic,… read more.